Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI SWOT - About
LQDA 
Liquidia Technologies Inc (LQDA)
Top performer
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
08/28/2025: LQDA (5-star) is a STRONG-BUY. BUY since 24 days. Profits (38.55%). Updated daily EoD!
Upturn Star Rating
Outstanding Performance
These Stocks/ETFs, based on Upturn Advisory, have historically outperformed the market, making them a top-tier choice for investors.
Number of Analysts
10 Analysts rated it
Moderately tracked stock, growing coverage, gaining market and investor attention.
1 Year Target Price $36.67
1 Year Target Price $36.67
| 6 | Strong Buy |
| 3 | Buy |
| 0 | Hold |
| 0 | Sell |
| 1 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit 106.89% | Avg. Invested days 38 | Today’s Advisory Strong Buy |
Upturn Star Rating | Upturn Advisory Performance  3.0 | Stock Returns Performance  5.0 |
| Profits based on simulation | Last Close 08/28/2025 |
Key Highlights
Company Size Mid-Cap Stock | Market Capitalization 2.36B USD | Price to earnings Ratio - | 1Y Target Price 36.67 |
Price to earnings Ratio - | 1Y Target Price 36.67 | ||
Volume (30-day avg) 10 | Beta 0.15 | 52 Weeks Range 8.75 - 28.82 | Updated Date 08/28/2025 |
52 Weeks Range 8.75 - 28.82 | Updated Date 08/28/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -1.82 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Earnings Date
Report Date 2025-08-12 | When - | Estimate -0.42 | Actual -0.49 |
Profitability
Profit Margin - | Operating Margin (TTM) -424.41% |
Management Effectiveness
Return on Assets (TTM) -39.74% | Return on Equity (TTM) -389.13% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 2437521712 | Price to Sales(TTM) 122.35 |
Enterprise Value 2437521712 | Price to Sales(TTM) 122.35 | ||
Enterprise Value to Revenue 126.15 | Enterprise Value to EBITDA -9.43 | Shares Outstanding 86091504 | Shares Floating 60079782 |
Shares Outstanding 86091504 | Shares Floating 60079782 | ||
Percent Insiders 13.61 | Percent Institutions 70.57 |
Upturn AI SWOT
Liquidia Technologies Inc
Company Overview
History and Background
Liquidia Technologies Inc. was founded in 2004, focusing on developing and commercializing novel drug delivery technologies, particularly in pulmonary hypertension. It has evolved from a technology platform company to a clinical-stage biopharmaceutical company.
Core Business Areas
- PH Business: Focuses on the development and commercialization of LIQ861 (Yutrepiau2122), an inhaled dry powder formulation of treprostinil for the treatment of pulmonary hypertension.
Leadership and Structure
The leadership team consists of key executives overseeing clinical development, regulatory affairs, and commercial strategy. The organizational structure is typical of a biopharmaceutical company with functional departments supporting drug development and potential commercialization.
Top Products and Market Share
Key Offerings
- Yutrepiau2122 (LIQ861): An inhaled dry powder formulation of treprostinil for the treatment of pulmonary hypertension. FDA approved November 2024. Market share is currently being established upon product launch. Competitors include United Therapeutics (UTHR) with Tyvaso and other prostacyclin analogs.
Market Dynamics
Industry Overview
The pharmaceutical industry, specifically the pulmonary hypertension (PH) market, is characterized by high unmet needs and a growing patient population. The market is competitive, with established players and ongoing innovation.
Positioning
Liquidia is positioned as an innovator with Yutrepiau2122, offering a potentially more convenient and effective inhaled therapy for PH patients compared to existing nebulized treprostinil products.
Total Addressable Market (TAM)
The total addressable market for pulmonary hypertension therapies is estimated to be in the billions of dollars annually. Liquidia is positioned to capture a portion of this TAM with Yutrepiau2122, dependent on market penetration and adoption.
Upturn SWOT Analysis
Strengths
- Novel technology platform (PRINTu00ae)
- FDA Approved Yutrepiau2122
- Potential for improved patient compliance with dry powder formulation
- Experienced management team
Weaknesses
- Reliance on single product (Yutrepiau2122)
- Limited commercialization experience
- History of operating losses
- Legal challenges from United Therapeutics (resolved)
Opportunities
- Expansion of Yutrepiau2122 into new indications
- Partnerships with larger pharmaceutical companies for commercialization
- Development of new products using PRINTu00ae technology
- Growing PH market
Threats
- Competition from established PH therapies
- Regulatory hurdles and delays
- Pricing pressures from payers
- Generic competition
Competitors and Market Share
Key Competitors
- UTHR
Competitive Landscape
Liquidia has a potentially more convenient delivery method for treprostinil compared to some competitors, but faces significant competition from established players like United Therapeutics with broader product portfolios and established market presence.
Growth Trajectory and Initiatives
Historical Growth: Historical growth has been focused on clinical development and regulatory milestones.
Future Projections: Future growth is projected to be driven by the commercialization of Yutrepiau2122 and potential expansion into new indications. Analyst estimates vary widely.
Recent Initiatives: Recent initiatives include the commercial launch of Yutrepiau2122, securing partnerships for distribution, and exploring new applications of PRINTu00ae technology.
Summary
Liquidia Technologies is a biopharmaceutical company with a focus on pulmonary hypertension. The company's future depends on the successful commercialization of Yutrepiau2122 and future product development. It faces competition from established players and needs to effectively execute its commercial strategy to achieve profitability. Recent FDA approval is positive.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Liquidia Technologies Inc. SEC Filings
- Analyst Reports
- Company Press Releases
Disclaimers:
The information provided is for informational purposes only and should not be construed as financial advice. Market share data is based on estimates and may not be precise. Investment decisions should be based on independent research and consultation with a qualified financial advisor.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Liquidia Technologies Inc
Exchange NASDAQ | Headquaters Morrisville, NC, United States | ||
IPO Launch date 2018-07-26 | CEO & Director Dr. Roger A. Jeffs Ph.D. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 170 | Website https://www.liquidia.com |
Full time employees 170 | Website https://www.liquidia.com | ||
Liquidia Corporation, a biopharmaceutical company, develops, manufactures, and commercializes various products for unmet patient needs in the United States. Its lead product candidates include YUTREPIA, an inhaled dry powder formulation of treprostinil for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD). The company also offers Remodulin, a treprostinil administered through continuous intravenous and subcutaneous infusion; and develops L606, an investigational liposomal formulation of treprostinil for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD). The company has a license agreement with Pharmosa Biopharm Inc to develop and commercialize L606, an inhaled sustained-release formulation of Treprostinil for the treatment of PAH and PH-ILD. Liquidia Corporation was founded in 2004 and is based in Morrisville, North Carolina.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.